T1	intervention 28 67	SB3 (a proposed trastuzumab biosimilar)
T2	control 72 93	trastuzumab reference
T3	eligibility 437 540	patients with early or locally advanced human epidermal growth factor receptor 2-positive breast cancer
T5	total-participants 1105 1108	875
T6	total-participants 1130 1133	764
T7	intervention-participants 1144 1147	380
T8	control-participants 1158 1161	384
T9	outcome 1279 1325	incidence of treatment-emergent adverse events
T10	iv-bin-percent 1362 1367	97.5%
T11	cv-bin-percent 1374 1379	96.1%
T12	outcome 1442 1480	overall incidence of antidrug antibody
T13	iv-bin-abs 1515 1516	3
T14	outcome 1533 1536	EFS
T17	outcome 1646 1668	EFS rates at 12 months
T18	iv-bin-percent 1672 1677	93.7%
T19	cv-bin-percent 1690 1695	93.4%
T4	outcome-Measure 1002 1008	safety
T15	outcome-Measure 1010 1024	immunogenicity
T16	outcome-Measure 1026 1051	event-free survival (EFS)
T20	outcome-Measure 1056 1073	overall survivalÂ 
